A Multicentre, Randomised, Double-blind, Parallel Group, Placebo-controlled, Time-to-first Asthma Exacerbation Phase III Efficacy and Safety Study of Benralizumab in Paediatric Patients with Severe Eosinophilic Asthma

Trial Identifier: D3250C00024
Sponsor: AstraZeneca
Collaborator:
Parexel
Start Date: April 2023
Primary Completion Date: May 2030
Study Completion Date: May 2032
Condition: Asthma

Available Languages

For questions about your Trial Results Summary, please see Sponsor contact section within your Trial Results Summary.

No documents have been posted yet.

Trial Locations

Country Location
AR Ciudad de Buenos Aire, AR, C1425DTG
AR Ciudad de Buenos Aires, AR, C1414AIF
AR Florencio Varela, AR, 1888
AR Florida, AR, B1602DQD
AR Lobos, AR, 7240
AR Mar del Plata, AR, B7600
AR Mendoza, AR, 5500
AR Mendoza, AR, M5500CCG
AR Rosario, AR, 2000
AR Santa Fe, AR, S3000ASF
ES Badalona, ES, 08916
ES Barcelona, ES, 8035
ES Benalmádena, ES, 29631
ES Esplugues de Llobregat, ES, 8950
FR Creteil, FR, 94010
FR Lyon, FR, 69394
FR Rouen Cedex, FR, 76031
GB London, GB, SE5 9RS
GB Manchester, GB, M13 9PL
IT Milano, IT, 20142
IT ROMA, IT, 00165
KR Cheongju-si, KR, 28644
KR Jung-gu, KR, 22332
KR Seoul, KR, 05505
KR Seoul, KR, 03080
PL Bialystok, PL, 15-879
PL Kraków, PL, 31-624
PL Łódź, PL, 90-302
PL Skarżysko-Kamienna, PL, 26-110
PL Tarnow, PL, 33-100
TW Kaohsiung, TW, 833
TW Taoyuan, TW, 333
US, CA Torrance, CA, US, 90505
US, FL Ocala, FL, US, 34471
US, KY Owensboro, KY, US, 42301
US, LA Lafayette, LA, US, 70508
US, MO Kansas City, MO, US, 64108
US, NJ Northfield, NJ, US, 08225
US, NY Bronx, NY, US, 10459
US, OH Cincinnati, OH, US, 45229
US, SC Charleston, SC, US, 29425
US, TX San Antonio, TX, US, 78229
US, TX Tyler, TX, US, 75708